Degenerative joint disease presents inherent complexity with treatment because of itsprogressive nature, and as a result, there are limited options for definitive treatment.Mesenchymal stem cells (MSCs) have been implicated in treatment of such chronicmusculoskeletal pathology, but their use in foot and ankle pathology is currentlylimited because of its relative novel introduction into the foot and ankle literature.This article compiles relevant literature regarding MSC injection for intra-articular pa-thology of the foot and ankle.

Download full article